

1 **Elevated blood glucose levels are associated with the progression of brain hypometabolism, and HDL-C**
2 **and APOE4 add to this association**

3 Aravind Lathika Rajendrakumar¹, Svetlana Ukraintseva¹, Olivia Bagley¹, Matt Duan¹, Anatoliy I. Yashin¹,
4 Konstantin G. Arbeev^{1,5,6}; for the Alzheimer’s Disease Neuroimaging Initiative⁵

5
6 **Abstract**

7 **Background:** Brain glucose hypometabolism has consistently been found in neurodegenerative disorders,
8 including Alzheimer’s disease (AD). High blood glucose and HDL cholesterol (HDL-C) levels have also been
9 linked to neurodegeneration and AD. However, there is limited understanding of the relationships
10 between dementia-related risk factors in the brain and blood.

11 **Methods:** A linear mixed model was used to examine the relationship between blood glucose and HDL-C
12 levels and the progression of brain hypometabolism, adjusting for APOE4 and other clinical covariates.
13 The hypometabolic convergence index (HCI) was measured by fluorodeoxyglucose-18 (FDG) positron
14 emission tomography (PET) in participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
15 Data visualizations were generated to understand the joint effects of plasma glucose, HDL-C, and APOE4
16 on HCI.

17 **Results:** There were 336 individuals (781 observations), of whom 22.62% had AD. The majority were male
18 (63.98%) and of white race, and 48.51% were carriers of APOE4. Over time, high blood glucose level was
19 associated with the progression of brain glucose hypometabolism ($\beta=0.33$, 95% CI: 0.02, 0.64, $p<0.05$). A
20 high plasma HDL-C level ($\beta=1.22$, 95% CI: 0.09, 2.35, $p<0.05$), more study visits ($\beta=1.67$, 95% CI: 1.37, 1.98,
21 $p<0.001$), and being an APOE4 allele carrier ($\beta=1.29$, 95% CI: 0.15, 2.42, $p<0.05$) were also significant
22 predictors of brain hypometabolism progression. APOE4 carrier status and number of visits account for
23 the largest proportion of the variance from the fixed effects model. Random effects due to participant

24 characteristics and fixed effects together accounted for 95.2% of the model variance. Subgroup analysis
25 revealed that these effects were observed only in those without AD.

26 **Conclusion:**

27 High plasma glucose levels facilitated the progression of brain hypometabolism. The effect was more
28 prominent in the *APOE4* double-carriers with elevated HDL-C. Elevated blood glucose may reflect systemic
29 insulin resistance, which could impair brain glucose uptake, resulting in brain hypometabolism.
30 Controlling blood glucose and HDL-C levels in *APOE4* carriers may improve brain metabolism, potentially
31 delaying the onset of dementia.

32 **Keywords**

33 Brain hypometabolism, Blood glucose, HDL cholesterol, *APOE4*, Alzheimer's disease, Hypometabolic
34 Convergence Index

36 **Background**

37 Glucose usage in the brain has been finely tuned throughout evolution.¹ Brain cells are highly energy-
38 dependent and require a constant supply of glucose for optimal functioning.² Glucose meets the energy
39 demands for a diverse range of activities, including brain signaling, neurotransmitter production, and
40 maintaining homeostasis.³ Due to this, multilayered mechanisms, including sensors, glucose transporters,
41 enzymes, and specific cell pathways, work together to ensure the availability of glucose.² Complex
42 learning processes in neurons and astrocytes are correlated with brain metabolism, which is directly
43 dependent on glucose usage.⁴ Exposure to insufficient glucose supply can harm memory and learning, and
44 prolonged insufficiency can potentially cause permanent brain alterations.³ Thus, any deviation from the
45 normal glucose uptake pattern in the brain might indicate a serious medical illness.⁵

46 Earlier neuroimaging studies have considerably expanded our knowledge of metabolic alterations in
47 dementia.^{6,7} Neuroimaging outcomes are superior to traditional cognitive assessments in detecting
48 related changes and correlate well with neuropathological changes in individuals with dementia.⁸ A
49 pattern of glucose deficit in the brain is noted for several neurodegenerative disorders, which can be
50 distinguished among the relevant conditions.⁹ In the case of Alzheimer's disease (AD), hypometabolism
51 begins much earlier than the actual onset of clinical symptoms and contributes to the further progression
52 of the disease.¹⁰ The [¹⁸F]-2-fluoro-2-deoxy-2-glucose (FDG) tracer-based positron emission tomography
53 (PET) is a widely used diagnostic method to ascertain the metabolic rate in different tissues. FDG mimics
54 glucose absorption and remains in the body longer than glucose. Studying its buildup in tissues helps
55 quantify the metabolic rate.¹¹ The FDG PET-derived hypometabolic convergence index can accurately
56 distinguish the AD signature brain hypometabolic pattern through automated brain image analysis.

57 Dementia subtypes, such as AD, have a complex, multifactorial etiology, stemming from an interplay
58 between aging, genetics, and the environment.¹² In this context, among the risk factors, hyperglycemia,
59 and particularly diabetes, are major concerns due to its rising global prevalence.¹³ Clinical features of
60 diabetes, such as abnormal insulin signaling and insulin resistance, are also pathological features of
61 dementia.¹⁴ Lipids are another risk factor that deserves attention in the control of dementia.¹⁵

62 Until recently, it was believed that elevated levels of HDL cholesterol were beneficial for health.¹⁶ Indeed,
63 numerous studies demonstrated protective associations between elevated HDL cholesterol levels and
64 reduced risk of heart disease, inflammatory conditions, and even cognitive decline.¹⁷ The protective
65 effects of HDL may be attributed to its antioxidant and anti-inflammatory properties, as well as its ability
66 to remove excess 'bad' cholesterol.¹⁸ Based on several such studies, it has even suggested that increasing
67 HDL levels or restoring its functions could be explored as a therapeutic option to combat inflammation
68 and AD.^{19,20}

69 Emerging evidence, however, has now challenged this established understanding.²¹ Despite these
70 findings, there is a lack of evidence regarding the connections between dementia risk factors in the brain
71 and in the blood. The combination of risk factors might drive individual differences in dementia
72 progression.¹⁰ Therefore, examining the combination of hypometabolism risk factors, such as blood
73 glucose and HDL-C levels, may provide more insights into individual differences in dementia progression.
74 The presence of the *APOE4* allele significantly increases the risk of developing AD.²² Despite numerous
75 research studies, many aspects of the role of *APOE4* in AD remain unclear, including its interaction with
76 dementia risk factors.²³ Due to these reasons, we also sought to explore how the effects were modified
77 when these risk factors were present in carriers of *APOE4*.

78

79 **Methods:**

80 **Data Source**

81 We conducted this analysis using the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. The
82 ADNI project was started in 2004 with Michael Weiner as the chief investigator. This project is a part of
83 public-private collaboration that includes major institutions across North America. ADNI encourages the
84 cost-free sharing of deep genotyped and phenotyped datasets with interested researchers worldwide.
85 ADNI collects biomarkers, brain scans, clinical data, and cognitive assessments from volunteer participants
86 based on a preset inclusion criteria. ADNI seeks to improve clinical prediction of AD and its treatment by
87 leveraging the wide variety of available longitudinal neuroimages, biomarkers, and cognitive scales.

88

89 **Details of FDG PET Imaging**

90 FDG PET imaging was performed on a subset of participants based on a standard protocol. Data gathered
91 within ADNI are allocated to different cores, each comprising experts specializing in corresponding

92 domains, tasked with efficiently managing the data.²⁴ There are two imaging cores, with PET imaging
93 falling under the jurisdiction of Banner Institute, which specifies parameters to maintain optimal imaging
94 quality. To ensure comparability and quality across various scanners, a 3D correction is applied to the
95 acquired images. For more information on PET measurements in the ADNI study, refer to Mueller et al.'s
96 publication.⁸

97

98 **Generation and Interpretation of Hypometabolic Convergence Index Scores**

99 We investigated the longitudinal changes in hypometabolic convergence index (HCI) as the study
100 outcome. HCI values were accessed from the BAIPETNMRCFDG dataset
101 (<https://adni.bitbucket.io/reference/baipetnmc.html>). The HCI was generated from comprehensive
102 whole-brain image analysis rather than regional examination of FDG PET brain images, and summarizes
103 the extent of brain hypometabolism in the form of z-scores.²⁵ These scores were obtained through voxel-
104 wise analysis of the images using Statistical Parametric Mapping (SPM) software.²⁶ An increasing HCI was
105 interpreted as indicative of greater brain hypometabolism.²⁵

106

107 **Covariate Extraction, Measurements, and Data linkage**

108 We extracted glucose and lipid biomarkers from the ADNINIGHTINGALELONG dataset. In ADNI, *APOE4*
109 was measured using DNA extracted by Cogenics from a 3 mL aliquot of EDTA blood collected during
110 participant screening visits.²⁷ Only rows containing values for all the variables were further considered for
111 the analysis. Information on smoking and alcohol use was obtained from the medical history file. Data
112 regarding systolic and diastolic blood pressure, sex, marital status, race, and education were derived from
113 the vitals and demographics datasets. Age was calculated as the difference in years between the

114 examination date and the date of birth for each participant over time. Diabetes medications were
115 extracted from the medication data using the Anatomical Therapeutic Classification (ATC) codes
116 (<https://www.who.int/tools/atc-ddd-toolkit/atc-classification>). When applicable, we used the visit code
117 and distinct participant identifier to link datasets. Once linked, a participant was considered to be taking
118 diabetes medication for all subsequent data following the initial prescription. We utilized the *tidyr*
119 package's *fill* function with the 'direction=down' option to propagate the diabetes medication use labels.

120

121 **Statistical Analysis**

122 We performed data analysis and visualizations using the R programming language (R version 4.3.2).²⁸ At
123 first, variable summaries measured at baseline were computed. For this, continuous variables were
124 presented as mean with standard deviation. Categorical variables were summarized as frequencies and
125 percentages. To depict correlations between continuous covariates at the baseline, we employed a
126 correlation heatmap. To assess longitudinal variations in plasma glucose and HDL-C levels, we pooled all
127 observations from all visits and calculated the coefficient of variation percentage (CV%). CV% was
128 computed by dividing the standard deviation by the mean and multiplying by 100. We generated a scatter
129 plot of the CV% for glucose and HDL-C distributions to assess their relationship. Additionally, we plotted
130 the CV% for these measures stratified by *APOE4* allele status and determined if the differences were
131 statistically significant using the Kruskal-Wallis test.

132 To examine the relationship between blood glucose, HDL-C levels, *APOE4* status, and the progression of
133 brain hypometabolism, and to account for the correlated data structure, we conducted a linear mixed
134 model analysis using the *lme4* package.²⁹ Variations between participants and visits were accounted for
135 by specifying random intercepts and varying slopes in the random effects part of the model. We analysed

136 multiple models with different combinations of terms and then selected the best model with the lowest
137 Akaike Information Criterion (AIC) values. This model was deemed the model with the minimum set of
138 variables that best explains the data. Model comparisons were performed using the anova built-in
139 function. For unbiased regression estimates in the optimal model, we employed restricted maximum
140 likelihood estimation. The Nelder-Mead optimizer was used to ensure model convergence.

141 To analyze the conditional and marginal variable contributions of the covariates in the parsimonious
142 mixed model, we utilized the hierarchical partitioning method.³⁰ This approach helps to understand how
143 *APOE4*, HDL-C, and glucose modify the HCl. We computed marginal means and corresponding 95%
144 confidence intervals (CI) to quantify the average change in HCl for these variables.

145 We also checked the functional relationship between glucose and HDL-C with HCl using generalized
146 additive mixed effect models (GAMM). The advantage of GAMM is that it is able to incorporate the
147 benefits of generalized additive models, i.e., nonlinear effects modeling, while also accounting for
148 correlations due to repeated measures.³¹ The AIC from both linear and nonlinear models were compared
149 to determine the most suitable functional relationship between the variables. A two-tailed p-value <0.05
150 was considered statistically significant. Additionally, we quantified and visualized individual heterogeneity
151 for the random effects terms specified in the optimal mixed effects model. Lastly, to assess the HCl
152 reduction associated with varying values of glucose and HDL-C, we generated a partial effect plot.

153 **Results**

154 **Sample description**

155 Data on 336 individuals (781 observations) were available for analysis after data linkage, with 22.62% of
156 participants diagnosed with AD (Supplementary Figure 1). Table 1 describes the baseline demographic
157 and clinical characteristics of the participants in this study. The participants were, on average, 75.43 years

158 old and had 15.6 years of education. The majority were male (63.98%) and White (93.45%). Over a third
159 (38%) had a smoking history, and 97.6% reported being ever married. The mean HbA1C and HDL-C levels
160 were 5.42 and 1.52, respectively. The mean systolic blood pressure (SBP) was relatively high at 135 mm
161 Hg, whereas the mean diastolic blood pressure (DBP) was below the normal reference level at 73.77 mm
162 Hg. Almost half (48.51%) were carriers of the *APOE4* allele. Figure 1 shows the distribution of longitudinal
163 CV% for glucose and HDL-C, as well as their relationship. In Figure 2, the distributions of longitudinal CV%
164 for glucose and HDL-C, stratified by *APOE4* allele status, are shown. Non-linear modeling (spline fit) of the
165 relationship between CV% for glucose and HDL-C supports a nonlinear relationship. P-values from the
166 Kruskal-Wallis test to see the influence of *APOE4* alleles on the CV% for glucose and HDL-C were non-
167 significant (0.78 and 0.56, respectively). Brain hypometabolism, measured by HCl, was higher in this
168 sample, with a mean of 15.06 (range 4.34 - 47.40). Initially, only 2 participants (0.60%) were using anti-
169 diabetes medication, but by the end of the follow-up, this number had risen to 10 (2.97%). As regards to
170 the baseline correlations, *APOE4* was positively correlated to HCl (Supplementary Figure 2). *APOE4* had
171 no strong correlations with either lipid subgroups and blood glucose. In those with AD, blood glucose and
172 HDL-C modelled using splines seems to favor a more non-linear relationship in comparison to those not
173 diagnosed with AD (Supplementary Figures 3-4).

174


175 **Table 1.** Characteristics of participants measured at baseline (781 observations, n=336)

Variables	Mean (Frequency)	SD	Range
Age (Years)	75.43	6.69	55.24 -89.00
Sex (Male)	215 (63.98%)		
Education (Years)	15.66	2.96	6-20

Blood Glucose (mmol/L)	5.42	0.87	2.99-10.47
HDL-C (mmol/L)	1.52	0.39	0.73 – 3.29
Race (White)	314 (93.45%)		
Married (Ever)	328 (97.61%)		
Smoking (Ever)	126 (37.50%)		
Alcohol (Ever)	11 (3.27%)		
AD	76 (22.61%)		
<i>APOE4</i>			
0	173 (51.48%)		
1	131 (38.98%)		
2	32 (9.52%)		
SBP (n=335)	135.12	16.59	90-201
DBP (n=335)	73.77	9.23	43-98
NonHDL-C	3.49	1.60	1.21-6.16
LDL-C	2.01	0.46	0.61 – 3.47
HCI	15.06	7.54	4.34 - 47.40

176 Note. SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; NonHDL-C = Non-High-density
177 lipoprotein cholesterol; LDL-C = Low-density lipoprotein cholesterol; HDL-C = High-density lipoprotein
178 cholesterol; HCI = Hypometabolic Convergence Index.
179

It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).




180

181 **Figure 1.** Histogram of longitudinal CV% for glucose and HDL-C, and a scatterplot with smoothed regression

182 line showing their relationship

183

184



185

186 **Figure 2.** Distribution of longitudinal CV% for glucose and HDL-C stratified by *APOE4* allele status

187 **Effect of Elevated Blood Glucose and HDL-C Variability on Brain Hypometabolism**

188 As shown in the Supplementary Table 1, Model 2 was selected for detailed analysis. Table 2 shows the
189 adjusted regression estimates from the optimal linear mixed model. More number of clinical visits
190 ($\beta=1.67$, 95% CI: 1.37, 1.98, $p<0.001$), and *APOE4* carrier status were the strongest predictors for the
191 decline in brain metabolism in ascending order respectively (Supplementary Figure 5). The contributions
192 of these variables to variance from fixed effects in the best model were also the highest. Over time, an
193 increase in plasma glucose was significantly associated with an increased area of brain hypometabolism
194 ($\beta=0.33$, $p<0.05$). None of the cholesterol markers except HDL-C were statistically significant in the
195 multivariate analysis ($\beta=1.22$, $p<0.05$). Additionally, age, sex, smoking, blood pressure, and race were not
196 significant predictors. The percentage variance of the fixed effects (marginal R-squared) was estimated at
197 4.5%. Supplementary Figure 6 elucidates the random effects represented by the clinical visits and
198 individual variability. Variance, combining both the fixed and random effects (conditional R-squared),
199 accounted for 95.2% of the model variance.

200

201 **Table 2.** Adjusted model estimates corresponding to the optimal linear mixed model for the HCl trend
202 outcome

Variable	Coefficient	95% CI	p-value
Glucose	0.33	0.02, 0.64	0.034*
HDL-C	1.22	0.09, 2.35	0.032*
<i>APOE4</i>	1.29	0.15,2.42	0.023*
Race (White)	2.85	-0.09,5.79	0.060
Visits	1.67	1.37,1.98	0.000***

203 Note. * $p < 0.05$; *** $p < 0.001$

204


205 **Functional Relationship Between Glycemic Variability, HDL-C Levels, and Their Interaction with *APOE4***
206 **on Brain Hypometabolism**

207 A comparison of effects plots (Supplementary Figure 7, Figure 3, and Figure 4) generated from linear and
208 additive mixed models (GAMM) indicates that glucose has a linear relationship with HCl. Conversely, HDL-
209 C showed a nonlinear relationship, which was preferred over the linear model. Additive mixed models
210 work similarly to linear mixed models, with the difference being that they allow for modeling complex
211 non-linear relationships of variables by fitting smooth functions.³¹ Partial effects here refer to the mean
212 effect in HCl due to the change in exposures while keeping the effects of other covariates held constant
213 in the model. The dose-response relationship between HDL-C and HCl was observed to decrease slightly,
214 stabilize and then decline after 2 mmol/L for higher values. According to Figure 4, elevated HDL-C reduces
215 brain metabolism even when glucose levels are optimal. Hypometabolism increases with each unit rise in
216 glucose, particularly above 7.5 mmol/L.


217 At this threshold, risk is evident even for low HDL-C values. Hence, it could be deduced that elevated
218 glucose values are an important risk factor for brain hypometabolism, and that its effects with HDL-C on
219 brain metabolism are non-linear. Supplementary Figure 8 complements this finding, showing substantial
220 differences in predicted HCl across stratified HDL-C categories of low, intermediate, and high levels.
221 Similar trends were evident in the interaction effects of blood glucose levels, HDL-C, and the *APOE4* allele
222 on HCl (Figure 5). The plot shows a dramatically pronounced decline in brain metabolism for increased
223 blood glucose levels and HDL-C in *APOE4* homozygous carriers compared to non-carriers and
224 heterozygous carriers. In addition, for better interpretation of the slopes, the marginal means for the HCl,
225 computed for the different combinations of these risk factors, are shown in Supplementary Table 2.

226 Compared to non-carriers with low HDL-C and high glucose, there was a more than 10-point increase in
227 predicted mean HCI for double *APOE4* carriers with high HDL-C.

228




230 **Figure 3.** Partial effects of Glucose and HDL-C levels on the HCI from the GAMM model. Note. TPRS (thin
231 plate regression splines) are basis functions that allow for model fitting of local segments of the exposure-
232 outcome relationship, which are then connected to provide a complete picture of the overall relationship.
233 Thin plate splines automatically determine the location and number of knots based on changes in the
234 values of the covariate.



235

236 **Figure 4.** The partial effect plot illustrates the combined effects of HDL-C and glucose levels on HCl. The
237 variable relationships are shown as a smoothed relationship as a function of these variables and are
238 estimated from the additive mixed model. In the plot, the black lines and black dots represent the contour
239 lines and observed data points, respectively. A change in color from green to orange reflects how the
240 relationship changes, i.e., from a negative to a positive partial effect. A partial effect of -1 means that a
241 one-unit increase in the predictor variable is associated with a one-unit decrease in the outcome variable,
242 and vice versa. It is evident that the partial effects vary at different levels of the predictor variables.

243



244

245 **Figure 5.** Plot showing the synergistic effects of blood glucose levels, HDL-C, and *APOE4* allele on HCl. The
246 predictions were generated from a model containing interaction terms for blood glucose levels, HDL-C,
247 and *APOE4*. Each window corresponds to the effects of the *APOE4* allele (0, 1, 2) and is shown specifically
248 for HDL-C categories (low, high, and intermediate, arbitrarily selected based on the data)

249

250 **Comparison of Subgroup Analysis to Identify Heterogeneity in Effects**

251 Given that the visualizations indicated a possible difference in the effects of the exposures in AD and non-
252 AD individuals, we prepared the data accordingly. Upon further investigation, we noted that the statistical
253 associations were limited to the non-AD subgroup (Supplementary Tables 3-4). Remarkably, the strength
254 of the associations for White race, HDL-C, and *APOE4* with HCl was much stronger in the stratified analysis
255 for this group. Overall, the effect size for glucose did not differ for the non-AD individuals compared to the
256 main analysis, whereas the clinical visits exhibited a diluted effect. For the AD group, both *APOE4* and visits
257 were still significantly associated with HCl. While the impact of visits was considerably stronger than in the
258 aggregated model, the effects of *APOE4* were strongly reversed, indicating a protective association.

259

260 **Discussion**

261 In this study of older adults, plasma glucose and HDL-C variability were significantly associated with a
262 reduction in brain metabolism, but only in individuals without AD. Importantly, these effects were
263 independent of *APOE4* and common confounders such as age, sex, and other lipids profiles. We also found
264 that the relationship of plasma glucose and HDL-C with brain metabolism operates independently of each
265 other. *APOE4* status and measurement visit were the strongest predictors of brain metabolism at the
266 population level. This is not surprising, as we demonstrated in our previous work using the ADNI data that
267 measurement visits provide more information than age alone.³² Measurement visits may indirectly reflect
268 patient characteristics, response, and observation time.³³

269 A hyperglycemic milieu can cause widespread systemic effects, thereby modulating physiological
270 responses.³⁴ It is important to note that the diabetes burden was quite low in our data. However, diabetes
271 is not an absolute requirement for the glucose to impact brain. Our findings are consistent with a previous
272 study which demonstrated that even midlife increase in glucose can accelerate dementia.³⁵ Although
273 hyperglycemia contributes to the development of dementia, its role in certain types of dementia such as
274 in AD remains to be established.³⁶ In our case, one possible reason could be that participants had AD at
275 baseline and, therefore, already had much lower brain metabolism. Therefore, it is much less likely that
276 glucose and HDL-C variations would have any impact. Also, *APOE4* is no more a risk factor since they had
277 already developed AD. Hyperglycemia-induced physiological changes are quite complex and usually do not
278 conform to the normal dose-response framework.³⁷ However, in our study, an increase in blood glucose
279 levels was linearly related to a decline in brain metabolism. This contradicted a previous study in which
280 cognitive decline was observed with both high and low blood sugar levels, and it worsened with age.³⁸
281 Nevertheless, high blood sugar-driven outcomes at the individual level are highly heterogeneous and also
282 depend on the combination of other risk factors and genes.^{39,40}
283 In our data, elevated HDL-C was stronger risk factor for brain hypometabolism than plasma glucose levels.
284 The role of lipids in dementia remains controversial. A meta-analysis of multiple studies published on lipid
285 subgroups shows that LDL-C could be a likely candidate risk factor for dementia, but there was no evidence
286 of involvement of HDL-C or other lipids.⁴¹ On the other hand, it is worth noting that high HDL-C levels could
287 negatively impact health and survival, including increased all-cause and cardiac-related mortality.
288 However, individuals in the mid-range levels of HDL-C seem to be protected.⁴² This was observed in the
289 'U-shaped' relationship between HDL-C levels and cognitive outcomes, with individuals having HDL-C
290 values above 2.50 mmol/L experiencing more than a two-fold increased risk of poor cognitive outcomes.⁴³
291 Such a relationship was also reported in a large-scale survival analysis of health insurance data exploring

292 dementia outcome. Similar to our study, LDL-C in this study did not influence dementia risk, except for a
293 minor increase in risk observed among statin users.⁴⁴

294 A study published in Lancet, that investigated whether HDL-C is a risk factor for incident dementia reported
295 a risk above 3.3 mmol/L.⁴⁵ Consistent with the previous findings, individuals aged above 75 years with
296 high HDL-C were at substantial risk for dementia. In stark contrast, lower HDL-C values were shown to be
297 protective against dementia.⁴⁵ This was in line with our finding. Based on the partial effects plots in our
298 study, HDL-C associated risk appeared to diminish beyond 2.25 mmol/L. However, these findings require
299 further validation, as there were only a few HDL-C values above this threshold in the data. It might be that
300 the HDL-C effects seen were due to the presence of AD, co-morbidities, or other age-related factors. In
301 such scenarios, high HDL would be merely reflective of these conditions rather than providing any real
302 health benefits.²⁰

303 *APOE4* carriage was associated with a greater metabolic decline compared to non-carriers for the
304 concomitant values of glucose and HDL-C. Notably, this interaction was particularly strong in individuals
305 with HDL-C levels above 2 mmol/L. It is intriguing that the direction of the predicted slope for brain
306 hypometabolism with glucose elevation was similar at lower HDL values across all *APOE4* isoforms, with
307 carriers experiencing a slightly higher metabolic decline. The observed interaction effects appear plausible
308 as *APOE4* have a direct link with cholesterol metabolism and lower HDL synthesis.⁴⁶⁻⁴⁸ In addition it has
309 been observed that mice with *APOE4* risk alleles exhibit a poor response to glucose spikes and inadequate
310 insulin production.⁴⁹ Individuals with *APOE4* risk alleles and high blood glucose were more likely to
311 experience greater risk for severe dementia and features of AD in late life.³⁵ First of all, carrying two
312 *APOE4* alleles is now considered a genetic form of AD by itself.⁵⁰ Our finding regarding the synergistic
313 effect modulated by *APOE4* double carriers is in firm agreement, showing a vastly different pattern of
314 hypometabolism compared to its other isoforms. Therefore, the effects in those without AD might actually
315 be congruent with preclinical AD.⁵¹ This should be kept in mind, especially in the context that the

316 diagnostic criteria for AD are still evolving.⁵¹ *APOE4* carrier status favors AD and dementia mainly through
317 promoting amyloid beta, increased phosphorylated tau, and contributing to neurodegeneration.^{27,52,53} It
318 is also recognized that *APOE4* variation can negatively impact mitochondrial respiration and energy
319 production, consequently leading to brain hypometabolism.⁵⁴ Other potential pathways include
320 neuroinflammation, blood-brain barrier dysfunction, gliosis, brain structural and functional changes,
321 demyelination and impaired clearance of toxic substances.⁵⁵⁻⁶⁰

322 In relevance to our work, it has already been demonstrated that *APOE4* variation adversely impacts the
323 ability of HDL-C to effectively sequester cholesterol by modifying HDL-C structurally. Not only does the
324 concentration of HDL matter, but also its size. For instance, individuals with AD and dementia tend to have
325 relatively smaller HDL particle sizes.⁶¹ We presume that *APOE4*-induced changes in the brain may make it
326 more vulnerable to the negative physiological effects of elevated glucose and other risk factors. As
327 corroborating evidence, we found no indication that longitudinal variability in glucose and HDL-C can be
328 attributed to *APOE4* alleles.

329 This study has several strengths including the availability of serial participant data and a well-characterized
330 cohort. Our study is among the first to illuminate the joint contributions of glucose, HDL-C, and *APOE4*
331 allele variations on brain hypometabolism. We were able to clearly demonstrate the change in relative
332 importance of these major risk factors through visualizations. This approach provides a more
333 comprehensive understanding of the potential pathophysiology, which may not be fully revealed when
334 examining these factors individually.

335 Our study had limitations. Blood glucose and HDL-C collection was not timed according to disease
336 pathology. The study did not account for comorbidity status or medication use as covariates, with the
337 exception of blood pressure, and diabetes. We have not specifically investigated the possibility of sexual
338 dimorphism in our results, nor have we considered the involvement of potential mechanisms such as

339 amyloid pathways or other inflammatory markers. Another constraint was the limited representation of
340 non-white samples, which restricted our ability to compare and explore differences across racial groups.
341 This, combined with the smaller sample size and selective recruitment in the cohort, may further limit the
342 generalizability of the findings. Lastly, there could be unmeasured confounding. Therefore, we
343 recommend replicating our findings in large cohorts and across multiple ethnicities to ascertain the
344 benefits of glucose and HDL reduction in diverse populations. Further studies may be conducted using
345 genetic variants that influence these exposures to gather causal evidence.

346

347 **Conclusion**

348 High blood glucose levels facilitated progression of cerebral hypometabolism in ADNI participants. The
349 negative impact of blood glucose on brain hypometabolism was aggravated by elevated HDL-C levels and
350 *APOE4* carrying status. High blood glucose levels may reflect systemic insulin resistance, which, in turn,
351 might impair brain glucose uptake, resulting in brain hypometabolism. While further validation is
352 warranted, controlling for plasma glucose/insulin resistance and HDL-C levels in *APOE4* carriers may
353 attenuate the decline in brain metabolism, potentially delaying dementia clinical onset.

354

355 **Abbreviations**

AD	Alzheimer's Disease
ADNI	Alzheimer's Disease Neuroimaging Initiative
ATC	Anatomical Therapeutic Classification
CV%	Coefficient of Variation Percentage
DBP	Diastolic Blood Pressure (DBP)

FDG	Fluorodeoxyglucose-18 (FDG)
GAMM	Generalized Additive Mixed Effect Models
HCI	Hypometabolic Convergence Index
HDL-C	High-density lipoprotein cholesterol
LDL-C	Low-density lipoprotein cholesterol
NonHDL-C	Non-High-density lipoprotein cholesterol
PET	Positron Emission Tomography
SBP	Systolic Blood Pressure (SBP)
SPM	Statistical Parametric Mapping
TPRS	Thin Plate Regression Splines

356

357

358 **References**

359 1. Harris JJ, Jolivet R, Attwell D. Synaptic Energy Use and Supply. *Neuron*. 2012;75(5):762–77.

360

361 2. Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: The role of glucose in
362 physiological and pathological brain function. Vol. 36, *Trends Neurosci*. 2013. 587–97.

363

364 3. Hertz L, Gibbs ME. What learning in day-old chickens can teach a neurochemist: focus on astrocyte
365 metabolism. *J Neurochem*. 2009;109(Suppl 1):10–6.

366

- 367 4. Turner DA, Adamson DC. Neuronal-Astrocyte Metabolic Interactions: Understanding the Transition
368 into Abnormal Astrocytoma Metabolism. *J Neuropathol Exp Neurol.* 2011 ;70(3):176.
369
- 370 5. Dienel GA. Fueling and Imaging Brain Activation. *ASN Neuro.* 2012;4(5).
371
- 372 6. Benson DF, Kuhl DE, Hawkins RA, Phelps ME, Cummings JL, Tsai SY. The Fluorodeoxyglucose 18F
373 Scan in Alzheimer’s Disease and Multi-infarct Dementia. *Arch Neurol.* 1983;40(12):711–4.
374
- 375 7. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, et al. Regional Cerebral Metabolic
376 Alterations in Dementia of the Alzheimer Type: Positron Emission Tomography with [18F]
377 fluorodeoxyglucose. *J Comput Assist Tomogr .* 1983;7(4):590–8.
378
- 379 8. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer’s Disease
380 Neuroimaging Initiative. *Neuroimaging Clin N Am.* 2005;15(4):869–77.
381
- 382 9. Han R, Liang J, Zhou B. Glucose metabolic dysfunction in neurodegenerative diseases—new
383 mechanistic insights and the potential of hypoxia as a prospective therapy targeting metabolic
384 reprogramming. *Int J Mol Sci.* 2021;22:5887.
385
- 386 10. Zilberter Y, Zilberter M. The vicious circle of hypometabolism in neurodegenerative diseases: Ways
387 and mechanisms of metabolic correction. *J Neurosci Res.* 2017;95:2217–35.

388

389 11. Pauwels EKJ, Coumou AW, Kostkiewicz M, Kairemo K. [18F] Fluoro-2-deoxy-D-glucose positron
390 emission tomography/computed tomography imaging in oncology: Initial staging and evaluation
391 of cancer therapy. *Med Princ Pract*. 2013;22(5):427–37.

392

393 12. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. *The Lancet*. 2006;368(9533):387–403.

394

395 13. Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease
396 pathology? *Nat Rev Neurol*. 2010;6(10):551–9.

397

398 14. Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD, Giau V Van. Type 3 Diabetes and Its Role
399 Implications in Alzheimer’s Disease. *Int J Mol Sci*. 2020;21(9):3165.

400

401 15. Zhu Y, Liu X, Zhu R, Zhao J, Wang Q. Lipid levels and the risk of dementia: A dose–response meta-
402 analysis of prospective cohort studies. *Ann Clin Transl Neurol*. 2022;9(3):311.

403

404 16. Rajagopal G, Suresh V, Sachan A. High-density lipoprotein cholesterol: How High. *Indian J*
405 *Endocrinol Metab*. 2012;16(2).

406

- 407 17. Bates KA, Sohrabi HR, Rainey-Smith SR, Weinborn M, Bucks RS, Rodrigues M, et al. Serum high-
408 density lipoprotein is associated with better cognitive function in a cross-sectional study of aging
409 women. *International Journal of Neuroscience*. 2017;127(3):243–52.
410
- 411 18. Barochia A V., Gordon EM, Kaler M, Cuento RA, Theard P, Figueroa DM, et al. High density
412 lipoproteins and type 2 inflammatory biomarkers are negatively correlated in atopic asthmatics. *J*
413 *Lipid Res*. 2017;58(8):1721.
414
- 415 19. Button EB, Robert J, Caffrey TM, Fan J, Zhao W, Wellington CL. HDL from an Alzheimer’s disease
416 perspective. *Curr Opin Lipidol*. 2019;30(3):234.
417
- 418 20. Trakaki A, Marsche G. High-Density Lipoprotein (HDL) in Allergy and Skin Diseases: Focus on
419 Immunomodulating Functions. *Biomedicines*. 2020;8(12):558.
420
- 421 21. Gong J, Harris K, Peters SAE, Woodward M. Serum lipid traits and the risk of dementia: A cohort
422 study of 254,575 women and 214,891 men in the UK Biobank. *EClinicalMedicine*. 2022;54(101695).
423
- 424 22. Pires M, Rego AC. Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and
425 Targeted Therapeutic Strategies. *Int J Mol Sci*. 2023;24(1):778.
426

- 427 23. Mosconi L, Herholz K, Prohovnik I, Nacmias B, Cristofaro MTR De, Fayyaz M, et al. Metabolic
428 interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain
429 reserve. *J Neurol Neurosurg Psychiatry*. 2005;76:15–23.
- 430
- 431 24. Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease
432 Neuroimaging Initiative (ADNI): MRI Methods. *J Magn Reson Imaging*. 2008;27(4):691.
- 433
- 434 25. Chen K, Ayutyanont N, Langbaum JBS, Fleisher AS, Reschke C, Lee W, et al. Characterizing
435 Alzheimer's disease using a hypometabolic convergence index. *Neuroimage*. 2011;56:52–60.
- 436
- 437 26. Caroli A, Prestia A, Chen K, Ayutyanont N, Landau SM, Madison CM, et al. Summary Metrics to
438 Assess Alzheimer Disease–Related Hypometabolic Pattern with 18F-FDG PET: Head-to-Head
439 Comparison. *J Nucl Med*. 2012;53(4):592–600.
- 440
- 441 27. Sudre CH, Cardoso MJ, Frost C, Barnes J, Barkhof F, Fox N, et al. APOE ϵ 4 status is associated with
442 white matter hyperintensities volume accumulation rate independent of AD diagnosis. *Neurobiol*
443 *Aging*. 2017;53:67–75.
- 444
- 445 28. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical
446 Computing, Vienna, Austria. 2021.
- 447

- 448 29. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J Stat
449 Softw [Internet]. 2015;67(1):1–48.
450
- 451 30. Lai J, Zou Y, Zhang S, Zhang X, Mao L, Zhang WH. glmm.hp: an R package for computing individual
452 effect of predictors in generalized linear mixed models. Journal of Plant Ecology [Internet]. 2022
453 Dec 1 [cited 2023 Jul 2];15(6):1302–7.
454
- 455 31. R package version 0.2-6. gamm4: Generalized Additive Mixed Models using “mgcv” and “lme4”
456 [Internet]. 2020 [cited 2024 Jul 16]. Available from: <https://CRAN.R-project.org/package=gamm4>.
457
- 458 32. Rajendrakumar AL, Arbeev KG, Bagley O, Yashin AI, Ukraintseva S, Initiative for the ADN. The SNP
459 rs6859 in NECTIN2 gene is associated with underlying heterogeneous trajectories of cognitive
460 changes in older adults. BMC Neurol. 2024;24(78).
461
- 462 33. Coulombe J, Moodie EEM, Shortreed SM, Renoux C. Estimating individualized treatment rules in
463 longitudinal studies with covariate-driven observation times. Stat Methods Med Res.
464 2023;32(5):868–84.
465
- 466 34. Mcmurry HS, Mendenhall E, Rajendrakumar A, Nambiar L, Satyanarayana S, Shivashankar R.
467 Coprevalence of type 2 diabetes mellitus and tuberculosis in low - income and middle - income
468 countries : A systematic review. Diabetes Metab Res Rev. 2019;35(2018).

469

470 35. Bangen KJ, Himali JJ, Beiser AS, Nation DA, Libon DJ, Fox CS, et al. Interaction between midlife blood
471 glucose and APOE genotype predicts later Alzheimer pathology. *J Alzheimers Dis.*
472 2016;53(4):1553–62.

473

474 36. Doney ASF, Bonney W, Jefferson E, Walesby KE, Bittern R, Trucco E, et al. Investigating the
475 Relationship Between Type 2 Diabetes and Dementia Using Electronic Medical Records in the
476 GoDARTS Bioresource. *Diabetes Care.* 2019;42(10):1973–80.

477

478 37. Rajendrakumar AL, Hapca SM, Nair ATN, Huang Y, Chourasia MK, Kwan RSY, et al. Competing risks
479 analysis for neutrophil to lymphocyte ratio as a predictor of diabetic retinopathy incidence in the
480 Scottish population. *BMC Med.* 2023;21(1):304.

481

482 38. Chakrabarty R, Yousuf S, Singh MP. Contributive Role of Hyperglycemia and Hypoglycemia Towards
483 the Development of Alzheimer’s Disease. *Mol Neurobiol.* 2022;59(7):4274–91.

484

485 39. Nair ATN, Wesolowska-Andersen A, Brorsson C, Rajendrakumar AL, Hapca S, Gan S, et al.
486 Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. *Nat Med.*
487 2022;28:982–8.

488

- 489 40. Lathika Rajendrakumar A, Narayanan Nair AT, Chourasia MK, Nangia C, Srinivasan S, Radha V, et
490 al. Multi-ancestry genome-wide association study of neutrophil-lymphocyte ratio and polygenic
491 risk score development to explore causal association with diabetic retinopathy. medRxiv. 2024 Jan
492 1;2024.06.19.24309194.
- 493
- 494 41. Sáiz-Vazquez O, Puente-Martínez A, Ubillos-Landa S, Pacheco-Bonrostro J, Santabárbara J.
495 Cholesterol and Alzheimer's Disease Risk: A Meta-Meta-Analysis. Brain Sci. 2020;10(6):386.
- 496
- 497 42. Liu C, Dhindsa D, Almuwaqqat Z, Ko YA, Mehta A, Alkhoder AA, et al. Association Between High-
498 Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk
499 Populations. JAMA Cardiol. 2022 Jul 1;7(7):672–80.
- 500
- 501 43. Huang H, Yang B, Yu R, Ouyang W, Tong J, Le Y. Very high high-density lipoprotein cholesterol may
502 be associated with higher risk of cognitive impairment in older adults. Nutr J. 2024;23(79).
- 503
- 504 44. Ferguson EL, Zimmerman SC, Jiang C, Choi M, Swinnerton K, Choudhary V, et al. Low- and High-
505 Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members
506 of a Large Health Care Plan. Neurology. 2023;101(21):e2172–84.

507

- 508 45. Monira Hussain S, Robb C, Tonkin AM, Lacaze P, T-J Chong T, Beilin LJ, et al. Association of plasma
509 high-density lipoprotein cholesterol level with risk of incident dementia: a cohort study of healthy
510 older adults. *Lancet Reg Health West Pac.* 2023;43(100963).
511
- 512 46. Dunk MM, Li J, Liu S, Casanova R, Chen JC, Espeland MA, et al. Associations of dietary cholesterol
513 and fat, blood lipids, and risk for dementia in older women vary by APOE genotype. *Alzheimer's*
514 *Dement.* 2023;19:5742–54.
515
- 516 47. Garcia AR, Finch C, Gatz M, Kraft T, Eid Rodriguez D, Cummings D, et al. APOE4 is associated with
517 elevated blood lipids and lower levels of innate immune biomarkers in a tropical Amerindian
518 subsistence population. Goldberg A, Perry GH, editors. *Elife.* 2021;10:e68231.
519
- 520 48. Hopkins PCR, Huang Y, McGuire JG, Pitas RE. Evidence for differential effects of apoE3 and apoE4
521 on HDL metabolism. *J Lipid Res.* 2002;43(11):1881–9.
522
- 523 49. Koren-Iton A, Salomon-Zimri S, Smolar A, Shavit-Stein E, Dori A, Chapman J, et al. Central and
524 Peripheral Mechanisms in ApoE4-Driven Diabetic Pathology. *Int J Mol Sci.* 2020;21(4):1289.
525
- 526 50. Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaqué-Alcázar L, et al. APOE4
527 homozygosity represents a distinct genetic form of Alzheimer's disease. *Nat Med.* 2024;30:1284–
528 91.

529

530 51. Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and
531 staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimer's Dement.* 2024;1–
532 27.

533

534 52. Lehmann M, Ghosh PM, Madison C, Karydas A, Coppola G, O'Neil JP, et al. Greater medial temporal
535 hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. *J Neurol*
536 *Neurosurg Psychiatry.* 2014;85(3):266–73.

537

538 53. Raulin AC, Doss S V., Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer's disease:
539 pathophysiology and therapeutic strategies. *Mol Neurodegeneration.* 2022;17(72).

540

541 54. Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, et al. Apolipoprotein E4 Domain
542 Interaction Mediates Detrimental Effects on Mitochondria and Is a Potential Therapeutic Target
543 for Alzheimer Disease *. *Journal of Biological Chemistry.* 2011;286(7):5215–21.

544

545 55. Flowers SA, Rebeck GW. APOE in the normal brain. *Neurobiol Dis.* 2020;136:104724.

546

547 56. Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to
548 blood-brain barrier dysfunction predicting cognitive decline. *Nature.* 2020;581(7806):71–6.

549

550 57. Matura S, Prvulovic D, Jurcoane A, Hartmann D, Miller J, Scheibe M, et al. Differential effects of the
551 ApoE4 genotype on brain structure and function. *Neuroimage*. 2014;89:81–91.

552

553 58. Operto G, Molinuevo JL, Cacciaglia R, Falcon C, Brugulat-Serrat A, Suárez-Calvet M, et al. Interactive
554 effect of age and APOE-ε4 allele load on white matter myelin content in cognitively normal middle-
555 aged subjects. *Neuroimage Clin*. 2019;24:101983.

556

557 59. Koutsodendris N, Blumenfeld J, Agrawal A, Traglia M, Grone B, Zilberter M, et al. Neuronal APOE4
558 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits. *Nat Aging*.
559 2023;3:275–96.

560

561 60. Liao F, Yoon H, Kim J. Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's
562 disease. *Curr Opin Lipidol*. 2017;28(1):67.

563

564 61. Zheng JJ, Hong B V., Agus J, Guo F, Lebrilla CB, Jin L, et al. Alzheimer's Disease Patients, Especially
565 ApoE4 Carriers, Have Significantly Reduced High-density Lipoprotein Particle Size Revealed by
566 Negative-stained Transmission Electron Microscopy. *Alzheimer's Dement*. 2022;18(e063375).

567

568 **Acknowledgements**

569 The authors would like to thank the ADNI team. Data collection and sharing for this project was funded
570 by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01

571 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded
572 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and
573 through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug
574 Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir,
575 Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La
576 Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen
577 Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research
578 & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx
579 Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging;
580 Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health
581 Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are
582 facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee
583 organization is the Northern California Institute for Research and Education, and the study is coordinated
584 by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are
585 disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

586

587 **Funding**

588 This research was funded by the National Institute on Aging of the National Institutes of Health under
589 award numbers R01AG070487 and R01AG062623. The content is solely the responsibility of the authors
590 and does not necessarily represent the official views of the National Institutes of Health.

591

592 **Author information**

593 **Authors and Affiliations**

594 ¹*Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, NC,*
595 *27708-0408, USA.*

596

597 **Contributions**

598 KA, SU, and ALR were involved in conceptualization, design and wrote the paper. OB, ALR, MD conducted
599 data curation and formal analysis. KA, and AIY provided guidance on data analysis, interpreted the
600 findings, and critically revised the manuscript. All authors have read and agreed to the published version
601 of the manuscript.

602

603 **Corresponding author**

604 ^{§§}Correspondence to Konstantin G. Arbeev, Email address: ka29@duke.edu

605

606 **Ethics declarations**

607 The studies involving human subjects were approved by the Duke University Health System Institutional
608 Review Board (Protocols Pro00105166 and Pro00105389). This publication includes only secondary
609 analyses of existing data available from ADNI, and does not include identifiable human data. Written
610 informed consent for ADNI participants was obtained by the ADNI in accordance with the local legislation
611 and ADNI requirements.

612

613 **Consent for Publication**

614 Not applicable

615 **Competing Interests**

616 The authors declare no competing interests.

617

618 **Additional information**

619 **Electronic Supplementary Material**

620 Supplementary Material 1

621